肺癌靶向治疗研究:以文献计量学和可视化分析描述的热点与趋势  

Targeted therapy of lung cancer:Research hotspots and publication trends described based on bibliometrics and visual analysis

作　　者：张秀梅[1,2] 翟运开[3] 赵杰[4] 赵萌 Zhang Xiumei;Zhai Yunkai;Zhao Jie;Zhao Meng(Institute of Scientific and Technical Information of China,Beijing 100038,China;Wanfang Data Co.,Ltd.,Beijing 100038,China;School of Management Engineering,Zhengzhou University,Henan Zhengzhou 450001,China;the First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450052,China)

机构地区：[1]中国科学技术信息研究所,北京100038 [2]万方数据股份有限公司,北京100038 [3]郑州大学管理工程学院,河南郑州450001 [4]郑州大学第一附属医院,河南郑州450052

出　　处：《现代肿瘤医学》2020年第19期3417-3427,共11页Journal of Modern Oncology

基　　金：国家重点研发计划“精准医学研究”重点专项(编号:2017YFC0909900)。

摘　　要：目的:通过文献计量学分析方法,阐述并分析肺癌靶向治疗的研究热点与趋势。方法:文章检索了万方数据库、Web of Science、SooPAT(中国专利)数据库近10年来国内外肺癌靶向治疗的相关文献,以文献计量学方法,分析并归类了肺癌靶向治疗的研究热点与时效变迁的趋势。结果:在万方数据库3 744篇肺癌靶向治疗的中文文章中,发现作用于表皮生长因子受体基因突变位点的分子靶向药物-吉非替尼治疗非小细胞肺癌的研究是中国学者近10年的主要研究热点;在近10年Web of Science数据库中检索到的810篇英文文章及参考文献显示,西妥昔单抗、贝伐单抗、纳武单抗、吉非替尼、厄洛替尼和环唑替尼为这10年肺癌治疗领域靶向治疗的热点药物,而多种靶向药物的联合治疗、晚期非小细胞肺癌的靶向治疗效果和肺癌靶向治疗后的脑转移也成为近5年该领域的国际关注热点;中国肺癌靶向治疗领域的254项有权专利的分析显示,申报了专利的主要药物包括酸敏感的吉非替尼-氟硼二吡咯衍生物、顺铂抗肺癌主动靶向隐形类脂质体等。结论:文章采用文献计量学的量化分析技术,呈现出近10年肺癌靶向治疗已成为该领域专业研究者持续关注的热点,而如何选择正确的靶向药物或药物组合方案来解决肺癌治疗中的耐药性问题,同时最大程度地减少患者的不良反应,以延长患者的生存率,应是未来集中研究的方向。Objective:To clarify and analyze the research hotspots and publication trends regarding targeted therapy of lung cancer by bibliometric analysis.Methods:We searched Wanfang database,Web of Science,SooPAT to retrieve papers regarding targeted treatment of lung cancer published in recent 10 years.Using bibliometric analysis method,we analyzed and classified the research hotspots and time-dependent publication trend of targeted therapy of lung cancer.Results:It was found based on 3 744 Chinese articles of targeted therapy of lung cancer published in Wanfang database that gefitinib,a molecular targeted drug acting on the mutation site of epidermal growth factor receptor gene,is the main research hotspot by Chinese scholars in the past 10 years.It was found based on 810 English articles retrieved from Web of Science as well as the cited references that cetuximab,bevacizumab,nivolumab,gefitinib,erlotinib and cyclozoltinib are the preferred drugs in the field of lung cancer treatment in the past 10 years.In addition,combined application of multiple targeted drug therapies,the effects of targeted therapy on advanced non-small cell lung cancer and brain metastasis after targeted therapy of lung cancer are also areas of interest worldwide in the past 5 years.According to the analysis on 254 Chinese granted patents regarding targeted therapy of lung cancer,the main drugs that have been applied for patent include acid sensitive gefitinib-boron-dipyrromethene derivatives,stealth liposomal cisplatin targeting for lung cancer,etc.Conclusion:Bibliometrics-based quantitative analysis shows that targeted therapy of lung cancer in the past 10 years has become an increasing area of interest in the field.Future studies will focus on how to choose the right targeted drugs or drug combination scheme to solve the drug resistance problem in lung cancer treatment,and at the same time to reduce the adverse reactions to the greatest extent,so as to prolong the survival of patients.

关 键 词：肺癌 靶向治疗 吉非替尼 表皮生长因子受体 文献计量学 

分 类 号：R734.2[医药卫生—肿瘤]